Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Cardiovascular Genetic Testing Market CAGR Analysis And Future Market Development

The cardiovascular genetic testing market has seen rapid expansion in recent years. Its size is expected to increase from $3.93 billion in 2025 to $4.35 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.8%. The historical growth of this market can be attributed to several factors, including a rise in awareness regarding inherited cardiovascular disorders, the development of molecular diagnostic capabilities, a reduction in the costs associated with genetic sequencing, an increase in the adoption of genetic counseling services, and enhanced research into cardiovascular genomics.

The cardiovascular genetic testing market is projected for substantial expansion in the coming years, reaching a valuation of $6.62 billion by 2030, driven by a compound annual growth rate (CAGR) of 11.0%. This anticipated growth during the forecast period stems from factors such as the escalating demand for precision medicine, the growing embrace of population-based genetic screening, the broadening scope of AI-driven variant interpretation, the deeper integration of genomics into clinical decision-making, and a heightened emphasis on preventive cardiovascular healthcare. Key trends expected over this period encompass a greater uptake of predictive genetic risk assessment, increased utilization of multigene panel testing, the advancing integration of bioinformatics and AI analytics, the widening application of pharmacogenomic testing, and a stronger commitment to personalized cardiovascular care.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33054&type=smp&utm_source=Blogs&utm_medium=Paid&utm_campaign=Jul_PR

Cardiovascular Genetic Testing Market Demand Drivers: What Is Fueling Industry Growth?

The rising occurrence of cardiovascular diseases is projected to drive the expansion of the cardiovascular genetic testing market moving forward. Cardiovascular diseases, or CVDs, refer to a collection of conditions impacting the heart and blood vessels, including ailments like heart attacks, strokes, and high blood pressure. The growing prevalence of these conditions is mainly due to an increase in sedentary lifestyles connected with urbanization, which contribute to obesity, hypertension, and metabolic disorders. The increasing incidence of cardiovascular diseases fuels the demand for cardiovascular genetic testing, as early detection of genetic risks allows for personalized prevention and treatment strategies to diminish the chance of severe heart complications. For instance, in January 2024, the American Heart Association, a US-based non-profit organization, stated that the age-adjusted death rate from cardiovascular disease rose to 233.3 per 100,000 in 2024, marking a 4.0% increase from 224.4 per 100,000 in 2023. Consequently, the escalating prevalence of cardiovascular disease is propelling the growth of the cardiovascular genetic testing market.

Cardiovascular Genetic Testing Market Segment Performance And Strategic Opportunities

The cardiovascular genetic testing market covered in this report is segmented –

1) By Testing Type: Predictive Testing; Carrier Testing; Prenatal And Newborn Testing; Diagnostic Testing; Pharmacogenomic Testing; Other Testing Types

2) By Disease: Inherited Cardiomyopathies; Hypertrophic Cardiomyopathy (HCM); Dilated Cardiomyopathy (DCM); Arrhythmia; Aortopathies; Other Diseases

3) By Technology: Cytogenetic Testing; Biochemical Testing; Molecular Testing

4) By Application: Chromosome Analysis; Genetic Disease Diagnosis; Cardiovascular Disease Diagnosis; Other Applications

5) By End User: Hospitals And Clinics; Diagnostic Laboratories; Research Institutions; Genetic Counseling Centers; Pharmaceutical Companies; Direct-To-Consumer Testing

Subsegments:

1) By Predictive Testing: Presymptomatic Risk Assessment; Familial Variant Screening; Polygenic Risk Evaluation; Late Onset Disease Prediction; Susceptibility Gene Testing

2) By Carrier Testing: Autosomal Recessive Carrier Screening; Linked Carrier Screening; Expanded Carrier Screening Panels; Single Gene Carrier Screening; Family History Based Carrier Testing

3) By Prenatal And Newborn Testing: Non Invasive Prenatal Genetic Testing; Invasive Prenatal Diagnostic Testing; Newborn Metabolic Screening; Congenital Heart Disease Genetic Screening; Neonatal Gene Panel Testing

4) By Diagnostic Testing: Single Gene Diagnostic Testing; Multigene Panel Diagnostic Testing; Whole Exome Diagnostic Testing; Whole Genome Diagnostic Testing; Variant Confirmation Testing

5) By Pharmacogenomic Testing: Drug Response Gene Testing; Adverse Drug Reaction Risk Testing; Dose Optimization Genetic Testing; Anticoagulant Response Testing; Cardiovascular Drug Metabolism Testing

6) By Other Testing Types: Cascade Family Testing; Population Based Genetic Screening; Research Use Genetic Testing; Confirmatory Follow Up Testing; Clinical Trial Genetic Testing

Cardiovascular Genetic Testing Market Innovation Trends: Which Developments Are Transforming The Industry?

Major companies within the cardiovascular genetic testing market are prioritizing the development of innovative solutions, such as tests initiated by clinicians. These solutions aim to guarantee the medical necessity of tests and customize them to a patient’s specific health profile, thereby decreasing unnecessary testing and associated costs. A clinician-ordered test is defined as a medical examination or diagnostic procedure requested by a healthcare professional to assess, monitor, or guide the management of an individual’s health condition. For example, in September 2025, Mass General Brigham, a US-based not-for-profit integrated academic healthcare system, in partnership with Broad Clinical Labs, a US-based genomic data generation laboratory, and Mass General Brigham Laboratory for Molecular Medicine, a US-based molecular diagnostic laboratory, introduced a genetic test designed to evaluate inherited risk for eight cardiovascular conditions. This clinician-ordered test is provided on a self-pay basis and assesses genetic predisposition to the eight specified conditions: atrial fibrillation, coronary artery disease, type 2 diabetes, elevated lipoprotein(a), hypercholesterolemia, hypertension, thoracic aortic aneurysm, and venous thromboembolism. Its creation leveraged genotype and clinical data from 236,393 participants in the NIH’s All of Us Research Program. Publicly available polygenic risk scores for each condition were integrated utilizing PRSmix, an elastic-net modeling approach that combines multiple component scores into a single, comprehensive risk score per disease. High-resolution genetic data is obtained through a clinical blended genome-exome assay at Broad Clinical Labs, with the CLIA-certified Mass General Brigham Laboratory for Molecular Medicine then interpreting the results and generating accessible reports for patients.

Cardiovascular Genetic Testing Market Key Players: Which Companies Shape Industry Competition?

Major companies operating in the cardiovascular genetic testing market are Labcorp Holdings Inc., Quest Diagnostics Inc., ICON plc, Illumina Inc., Apollo Hospitals, OPKO Health Inc., Revvity Inc., ARUP Laboratories Inc., Mayo Clinic Laboratories, Fulgent Genetics Inc., MedGenome Inc., Genome Medical, PreventionGenetics, Eurofins Genomics LLC, Blueprint Genetics Inc., MapmyGenome, GENinCode, Allelica Srl, Rocket Pharma Inc., and Health in Code SL.

Access The Complete Cardiovascular Genetic Testing Market Report:

https://www.thebusinessresearchcompany.com/report/cardiovascular-genetic-testing-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Jul_PR

Cardiovascular Genetic Testing Market Regional Distribution: Which Areas Drive Market Expansion?

North America was the largest region in the cardiovascular genetic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiovascular genetic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model